# Curcumin Rewires the Tumor Metabolic Landscape: Mechanisms and Clinical Prospects

**Authors:** Dingya Sun, Dun Hu, Jialu Wang, Xin Li, Jun Peng, Shan Wang

PMC · DOI: 10.3390/nu18010053 · Nutrients · 2025-12-23

## TL;DR

Curcumin, a natural compound, can alter tumor metabolism through multiple pathways, offering potential for cancer treatment.

## Contribution

This paper systematically reviews curcumin's effects on tumor metabolic reprogramming and its underlying molecular mechanisms.

## Key findings

- Curcumin modulates key glycolytic enzymes and transporters in tumor cells.
- It inhibits lipid and amino acid metabolism proteins and induces ferroptosis via the SLC7A11/GPX4 axis.
- Curcumin's effects depend on cell type and tumor model, influencing energy and biosynthetic metabolism.

## Abstract

Metabolic reprogramming is a fundamental hallmark and a key driver of malignant tumors. By reshaping glucose, lipid, and amino acid metabolism, as well as mitochondrial function, it sustains the abnormal proliferation and survival of tumor cells, making it a crucial target for anti-tumor therapy. Curcumin, a natural multi-target compound, exhibits unique advantages in intervening in tumor metabolic reprogramming due to its low toxicity and broad-spectrum regulatory properties. In various tumor models, it can directly modulate the activity of key glycolytic enzymes, such as hexokinase 2, lactate dehydrogenase A, and pyruvate kinase M2, as well as transporters like glucose transporter 1. Furthermore, it inhibits the expression of proteins related to lipid metabolism, including fatty acid synthase and stearoyl-CoA desaturase 1, while also intervening in amino acid metabolic networks, such as glutaminase and branched-chain amino acid transaminase. Additionally, curcumin targets mitochondrial function and reactive oxygen species balance, creating multi-dimensional intervention effects through various pathways, including the induction of ferroptosis by regulating the SLC7A11/GPX4 axis and modulating gut microbiota metabolism. Its mechanism of action involves the synergistic regulation of key signaling pathways, including phosphoinositide 3-kinase/Akt, NF-κB, AMP-activated protein kinase, and hypoxia-inducible factor-1alpha. Furthermore, its specific effect profile demonstrates significant dependency on cell type and tumor model. This article systematically reviews the regulatory effects of curcumin on these critical metabolic processes and pathways in tumor metabolic reprogramming, revealing its molecular mechanisms in disrupting tumor growth and progression by targeting energy and biosynthetic metabolism. These findings provide a significant theoretical foundation and a preclinical research perspective for the development of natural antitumor drugs based on metabolic regulation, as well as for optimizing combination therapy strategies.

## Linked entities

- **Genes:** HK2 (hexokinase 2) [NCBI Gene 374044], PGLCT (plastidic GLC translocator) [NCBI Gene 831472], FASN1 (Fatty acid synthase 1) [NCBI Gene 33524], SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Proteins:** HK2 (hexokinase 2), PGLCT (plastidic GLC translocator), FASN1 (Fatty acid synthase 1), SLC7A11 (solute carrier family 7 member 11), GPX4 (glutathione peroxidase 4)
- **Chemicals:** curcumin (PubChem CID 969516)
- **Diseases:** tumor (MONDO:0005070), cancer (MONDO:0004992)

## Full-text entities

- **Genes:** GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, FASN (fatty acid synthase) [NCBI Gene 2194] {aka FAS, OA-519, SDR27X1}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, GLS (glutaminase) [NCBI Gene 2744] {aka AAD20, CASGID, DEE71, EIEE71, GAC, GAM}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}
- **Diseases:** Tumor (MESH:D009369), toxicity (MESH:D064420)
- **Chemicals:** reactive oxygen species (MESH:D017382), glucose (MESH:D005947), amino acid (MESH:D000596), Curcumin (MESH:D003474), lipid (MESH:D008055)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12788039/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12788039/full.md

## References

232 references — full list in the complete paper: https://tomesphere.com/paper/PMC12788039/full.md

---
Source: https://tomesphere.com/paper/PMC12788039